Deciphera Pharmaceuticals, Inc. (DCPH)

14.23 -0.49 (-3.33%) At close: 04:00PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 355

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Steven L. Hoerter	President, CEO & Director	1.24M	N/A	1971
Mr. Thomas Patrick Kelly J.D.	Executive VP, CFO & Treasurer	778.85k	N/A	1971
Mr. Daniel C. Martin	Senior VP & Chief Commercial Officer	711.42k	N/A	1975
Dr. Matthew L. Sherman M.D.	Executive VP & Chief Medical Officer	865.62k	N/A	1956
Dr. Kevin Brodbeck Ph.D.	Senior VP & Chief Technical Officer	N/A	N/A	N/A
Dr. Dashyant Dhanak Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1961
Jennifer Larson	Senior Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. Jeffrey M. Held J.D.	Senior VP & General Counsel	N/A	N/A	N/A
Ms. Lisa Amaya Price	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Ms. Jama Pitman	Senior VP & Chief Development Officer	N/A	N/A	1980

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate governance

Deciphera Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.